Journal article

Immunosuppressive activities of adenosine in cancer

Bertrand Allard, Paul A Beavis, Phillip K Darcy, John Stagg

CURRENT OPINION IN PHARMACOLOGY | ELSEVIER SCI LTD | Published : 2016

Abstract

Multiple immunosuppressive mechanisms impede anti-tumor immunity. Among them, the accumulation of extracellular adenosine is a potent and widespread strategy exploited by tumors to escape immunosurveillance through the activation of purinergic receptors. In the immune system, engagement of A2a and A2b adenosine receptors is a critical regulatory mechanism that protects tissues against excessive immune reactions. In tumors, this pathway is hijacked and hinders anti-tumor immunity, promoting cancer progression. Different groups have highlighted the therapeutic potential of blocking CD73-dependent adenosine-mediated immunosuppression to reinstate anti-tumor immunity. Phase clinical trials evalu..

View full abstract

Grants

Awarded by National Breast Cancer Fellowship


Funding Acknowledgements

B Allard is supported by a MITACS Elevate fellowship. J Stagg is supported by the Famille Jean-Guy Sabourin Research Chair and by a CIHR New Investigator Award. PA Beavis was supported by a National Breast Cancer Fellowship (ID# PF-14-008) and P. K. Darcy was supported by a National Health and Medical Research Council (NHMRC) Senior Research Fellowship and project grants from the NHMRC and Cancer Council of Victoria.